Clinical Trial

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2021-07-08; most recent amendment 2024-12-03.
Status change: Recruiting → Active, Not Recruiting 2024-12-03
Status change: Not Yet Recruiting → Recruiting 2021-11-12
Trial Details
NCT Number NCT04967521
Lead Sponsor Sarcoma Alliance for Research through Collaboration
Collaborators: Eli Lilly and Company
Conditions Advanced Dedifferentiated Liposarcoma
Enrollment 108 participants
Start Date 2021-11-11
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-06